CL2021000724A1 - Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 - Google Patents
Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3Info
- Publication number
- CL2021000724A1 CL2021000724A1 CL2021000724A CL2021000724A CL2021000724A1 CL 2021000724 A1 CL2021000724 A1 CL 2021000724A1 CL 2021000724 A CL2021000724 A CL 2021000724A CL 2021000724 A CL2021000724 A CL 2021000724A CL 2021000724 A1 CL2021000724 A1 CL 2021000724A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- disease
- aging
- compositions
- treating
- Prior art date
Links
- 230000032683 aging Effects 0.000 title 1
- 230000006866 deterioration Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000019430 Motor disease Diseases 0.000 abstract 1
- 206010068871 Myotonic dystrophy Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000724A1 true CL2021000724A1 (es) | 2021-10-15 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000724A CL2021000724A1 (es) | 2018-09-26 | 2021-03-23 | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (https=) |
| JP (2) | JP7528065B2 (https=) |
| KR (1) | KR20210065950A (https=) |
| CN (1) | CN112789044A (https=) |
| AU (1) | AU2019346456A1 (https=) |
| BR (1) | BR112021004938A2 (https=) |
| CL (1) | CL2021000724A1 (https=) |
| CO (1) | CO2021003713A2 (https=) |
| EA (1) | EA202190463A1 (https=) |
| IL (1) | IL281578A (https=) |
| MA (1) | MA53743A (https=) |
| MX (1) | MX2021002967A (https=) |
| SG (1) | SG11202102105VA (https=) |
| TW (1) | TW202027752A (https=) |
| WO (1) | WO2020069008A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113689A1 (en) | 2018-09-25 | 2020-04-02 | Antabio Sas | Indane derivatives for use in the treatment of bacterial infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| MX2011011080A (es) | 2009-04-22 | 2012-02-23 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida. |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| MY199462A (en) * | 2017-04-05 | 2023-10-30 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
-
2019
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko not_active Withdrawn
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en not_active Ceased
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004938A2 (pt) | 2021-06-01 |
| JP7528065B2 (ja) | 2024-08-05 |
| MA53743A (fr) | 2022-01-05 |
| TW202027752A (zh) | 2020-08-01 |
| CO2021003713A2 (es) | 2021-04-08 |
| AU2019346456A1 (en) | 2021-04-15 |
| KR20210065950A (ko) | 2021-06-04 |
| JP2024153742A (ja) | 2024-10-29 |
| EP3856195A4 (en) | 2022-06-22 |
| CN112789044A (zh) | 2021-05-11 |
| EA202190463A1 (ru) | 2021-06-29 |
| SG11202102105VA (en) | 2021-04-29 |
| MX2021002967A (es) | 2021-08-11 |
| IL281578A (en) | 2021-05-31 |
| JP2022502441A (ja) | 2022-01-11 |
| CA3111433A1 (en) | 2020-04-02 |
| EP3856195A1 (en) | 2021-08-04 |
| WO2020069008A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012164A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| MX388385B (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| BR112018069533A2 (pt) | tratamento de condições alérgicas oculares com ciclodextrinas | |
| CO2020003932A2 (es) | Compuesto heterocíclico | |
| CL2019000787A1 (es) | Métodos para tratar trastornos mitocondriales y metabólicos. | |
| MX376257B (es) | Moduladores alostericos de receptores de acetilcolina nicotinicos. | |
| ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
| DOP2017000118A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
| MX2016010777A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer. | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| ECSP17028459A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PH12019501371A1 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES | |
| PH12021550973A1 (en) | Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| CO2021003713A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
| MX2019014310A (es) | Agente para prevenir o tratar atrofia cerebral. | |
| WO2020117031A3 (en) | Composition and method for inhibiting amyloid beta accumulation and/or aggregation | |
| JP1724082S (ja) | 保護眼鏡 | |
| EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| JP1724081S (ja) | 保護眼鏡 | |
| AR120165A1 (es) | Composiciones de oligonucleótidos y métodos de uso de las mismas | |
| JP1724123S (ja) | 保護眼鏡 |